Analysts forecast that Heron Therapeutics Inc (NASDAQ:HRTX) will announce earnings per share (EPS) of ($0.48) for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Heron Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.60). Heron Therapeutics posted earnings of ($0.77) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 37.7%. The business is expected to report its next quarterly earnings results on Monday, November 5th.

On average, analysts expect that Heron Therapeutics will report full-year earnings of ($2.22) per share for the current year, with EPS estimates ranging from ($2.56) to ($1.86). For the next financial year, analysts expect that the business will report earnings of ($0.59) per share, with EPS estimates ranging from ($1.48) to $0.45. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported ($0.54) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.14. The firm had revenue of $17.28 million for the quarter, compared to analyst estimates of $12.82 million. Heron Therapeutics had a negative net margin of 411.41% and a negative return on equity of 112.35%. The business’s revenue for the quarter was up 103.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.80) EPS.

Several analysts have recently commented on HRTX shares. Cantor Fitzgerald set a $40.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 24th. BidaskClub raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 19th. Oppenheimer set a $34.00 target price on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Thursday, May 10th. Cowen reiterated a “buy” rating and issued a $48.00 target price on shares of Heron Therapeutics in a report on Tuesday, May 8th. Finally, Mizuho reiterated a “buy” rating and issued a $41.00 target price on shares of Heron Therapeutics in a report on Friday, June 22nd. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Heron Therapeutics has a consensus rating of “Buy” and an average target price of $50.09.

Shares of HRTX stock traded up $0.10 during trading on Monday, hitting $38.20. 704,400 shares of the stock traded hands, compared to its average volume of 1,213,213. The firm has a market cap of $3.01 billion, a PE ratio of 10.47 and a beta of 1.56. Heron Therapeutics has a 52-week low of $14.40 and a 52-week high of $42.90.

In related news, President Robert Rosen sold 129,469 shares of Heron Therapeutics stock in a transaction that occurred on Friday, June 29th. The shares were sold at an average price of $39.59, for a total value of $5,125,677.71. Following the completion of the sale, the president now owns 132,109 shares in the company, valued at approximately $5,230,195.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Barry D. Quart sold 50,000 shares of Heron Therapeutics stock in a transaction that occurred on Thursday, June 21st. The shares were sold at an average price of $39.05, for a total transaction of $1,952,500.00. Following the completion of the sale, the chief executive officer now owns 69,600 shares of the company’s stock, valued at approximately $2,717,880. The disclosure for this sale can be found here. Insiders sold a total of 440,469 shares of company stock valued at $17,218,958 in the last quarter. 16.20% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of HRTX. Eagle Asset Management Inc. acquired a new stake in Heron Therapeutics in the 1st quarter valued at approximately $50,005,000. Carillon Tower Advisers Inc. acquired a new stake in Heron Therapeutics in the 1st quarter valued at approximately $33,651,000. BlackRock Inc. increased its holdings in Heron Therapeutics by 29.4% in the 2nd quarter. BlackRock Inc. now owns 4,544,731 shares of the biotechnology company’s stock valued at $176,563,000 after purchasing an additional 1,032,010 shares during the last quarter. FMR LLC grew its stake in shares of Heron Therapeutics by 6.5% in the second quarter. FMR LLC now owns 11,290,956 shares of the biotechnology company’s stock worth $438,654,000 after acquiring an additional 693,699 shares in the last quarter. Finally, Nexthera Capital LP acquired a new position in shares of Heron Therapeutics in the first quarter worth $11,288,000.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Article: What does RSI mean?

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.